177 related articles for article (PubMed ID: 21453284)
1. MVA and NYVAC as vaccines against emergent infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Perdiguero B; Esteban M
Curr Gene Ther; 2011 Jun; 11(3):189-217. PubMed ID: 21453284
[TBL] [Abstract][Full Text] [Related]
2. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Esteban M
Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
[TBL] [Abstract][Full Text] [Related]
3. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
Esteban M
Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840
[TBL] [Abstract][Full Text] [Related]
4. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
[TBL] [Abstract][Full Text] [Related]
5. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
Guerra S; Nájera JL; González JM; López-Fernández LA; Climent N; Gatell JM; Gallart T; Esteban M
J Virol; 2007 Aug; 81(16):8707-21. PubMed ID: 17537851
[TBL] [Abstract][Full Text] [Related]
6. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
Verheust C; Goossens M; Pauwels K; Breyer D
Vaccine; 2012 Mar; 30(16):2623-32. PubMed ID: 22342706
[TBL] [Abstract][Full Text] [Related]
7. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
Sutter G; Staib C
Curr Drug Targets Infect Disord; 2003 Sep; 3(3):263-71. PubMed ID: 14529359
[TBL] [Abstract][Full Text] [Related]
8. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
Volz A; Fux R; Langenmayer MC; Sutter G
Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):464-72. PubMed ID: 26697713
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
10. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
Karkhanis LU; Ross TM
Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
[TBL] [Abstract][Full Text] [Related]
11. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
Price PJ; Torres-Domínguez LE; Brandmüller C; Sutter G; Lehmann MH
Vaccine; 2013 Sep; 31(39):4231-4. PubMed ID: 23523404
[TBL] [Abstract][Full Text] [Related]
12. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
16. Recombinant MVA vaccines: dispelling the myths.
Cottingham MG; Carroll MW
Vaccine; 2013 Sep; 31(39):4247-51. PubMed ID: 23523407
[TBL] [Abstract][Full Text] [Related]
17. New viral vectors for infectious diseases and cancer.
Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
[TBL] [Abstract][Full Text] [Related]
18. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.
Chahroudi A; Garber DA; Reeves P; Liu L; Kalman D; Feinberg MB
J Virol; 2006 Sep; 80(17):8469-81. PubMed ID: 16912297
[TBL] [Abstract][Full Text] [Related]
19. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
[TBL] [Abstract][Full Text] [Related]
20. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
